Cell and gene therapies are transforming modern medicine, offering new hope for patients with complex and previously untreatable diseases. As innovation advances, the industry must overcome challenges in manufacturing, regulation and scalability to unlock the full potential of these groundbreaking therapies.
Manual sampling cycles leave bioreactor control decisions hours behind culture dynamics. Process Raman spectroscopy offers continuous, real-time measurement of critical parameters, enabling true closed-loop control in perfusion and continuous bioprocessing applications where measurement lag directly impacts yield and product quality.
The biopharmaceutical industry has embraced Pharma 4.0 concepts, but the measurement infrastructure required to realise autonomous facilities and continuous bioprocessing remains underdeveloped. Process Raman spectroscopy offers continuous, non-destructive monitoring at frequencies aligned with cell culture dynamics, bridging the gap between control system capabilities and available data.
Join Dr. Zi Li, Associate Director of Formulation at BioDuro, to explore how polymorph screening, salt formation and cocrystallisation can resolve dissolution, stability and IP challenges in early-stage drug development.
EPR Issue 1 includes articles on manufacturing, drug delivery, environmental monitoring, analytical techniques and more.
This In-Depth Focus explores how BPCs, RMMs and AI-enabled analytics are being evaluated as a tool to enhance aseptic manufacturing, bioburden testing and monitoring.
A recent market report projecting the combined NIR and Raman spectroscopy sector will reach $2.35 billion in 2026 underscores the rapid adoption of vibrational spectroscopy across biopharmaceutical manufacturing, with AI-enhanced Raman tools increasingly being deployed for real-time quality control.
EPR Issue 1 includes articles on manufacturing, drug delivery, environmental monitoring, analytical techniques and more.
General Manager Brian Morrissey discusses his companyâs acquisition of fellow Beta-Lactam manufacturer Athlone Laboratories and its implications for an evolving industry.
Sartorius BIA Separations illustrates a promising alternative approach for efficient lentiviral vector purification that delivers a scalable, GMP-ready biomanufacturing solution.
EPRâs 2026 pharma manufacturing trends report covers the key developments in supply chain, quality, drug development, new modalities and beyond.
Essential for any medicine that must be sterile and safe for injection, ROISâ Miguel Ăngel Ortega SĂĄnchez presents the case for outsourcing WFI production to a trusted partner.
Experts from WuXi Biologics explain how next-generation cell line development with targeted integration advances the field by enabling the production of clonal cell lines with predictable transgene copies at specific, predefined sites in the host genome.
The three-day MSS2026 event takes place in September in Slovenia, with online attendance options also available.
People, not platforms, will define the next era of innovation, explain Chiesiâs Executive VP of R&D Diego Ardigò and Nick Petschek, EMEA Managing Director at Kotter.
As vaccines are buffeted by political pressures, the CDMO discussed its growth approach and some of its key collaborations.
Named CEO of the Year at CPHI Frankfurt, the CDMOâs head talks about the type of company he and his team are building.
The critical role of identification and documentation in contamination control.
Here, Hexagon outlines a four-step plan to address silos and scale-up challenges, drawing on the experience of leading pharma firms like Pfizer.
CDMOs weigh up how to meet manufacturing demands across oral solid doses, monoclonal antibodies, ADCs and beyond.